Fluimucil – a mucolytic drug with antioxidant properties. It dilutes sputum, increases its volume and facilitates its separation.
The action of acetylcysteine is associated with the ability of its sulfhydryl groups to break the intramolecular and intermolecular disulfide bonds of acid mucopolysaccharides of sputum, which leads to the depolarization of mucoproteins and a decrease in the viscosity of sputum.
Preserves activity in the presence of purulent sputum.
It has an antioxidant effect due to the presence of the SH group capable of neutralizing electrophilic oxidative toxins.
It also has an anti-inflammatory effect (due to the suppression of the formation of free radicals and active oxygen-containing substances responsible for the development of inflammation in the lung tissue).
Respiratory diseases, accompanied by the formation of sputum of increased viscosity (acute and chronic bronchitis, pneumonia, bronchiectasis, cystic fibrosis, bronchial asthma) to facilitate the discharge of mucus in sinusitis.
Diseases of the respiratory system, accompanied by the formation of sputum with increased viscosity.
Hypersensitivity to acetylcysteine, peptic ulcer of the stomach and duodenum in the acute stage.
Caution should be given to patients with liver and kidney disease.
Use during pregnancy and lactation
Use during pregnancy and breastfeeding is only possible if the intended benefits to the mother outweigh the potential risk to the fetus or baby.
For patients with bronchial asthma and obstructive bronchitis, fluimucil can only be prescribed if adequate sputum drainage is provided.
1 ampoule (3 ml) contains acetylcysteine ??300 mg
disodium edetate – 3 mg
sodium hydroxide – 74 mg
water for injection – up to 3 ml.
From the digestive system: rarely – heartburn, nausea, vomiting, diarrhea, stomatitis.
Allergic reactions: rarely – skin rash, itching, urticaria, bronchospasm.
Other: rarely – nosebleeds, tinnitus, collapse, decreased platelet aggregation.
Local reactions: with parenteral administration, a slight burning sensation at the injection site is possible with inhalation administration – a reflex cough, local respiratory tract irritation, stomatitis, rarely rhinitis – bronchospasm (in this case, the appointment of bronchodilators is necessary).
The simultaneous use of Fluimucil with antitussive agents may increase sputum congestion due to suppression of the cough reflex.
When used simultaneously with antibiotics such as tetracyclines (excluding doxycycline), ampicillin, amphotericin B, their interaction with the thiol group of acetylcysteine is possible, which leads to a decrease in the activity of both drugs, therefore, the interval between taking acetylcysteine and antibiotics should be at least 2 hours.
Acetylcysteine reduces the hepatotoxic effect of paracetamol.
Pharmaceutically incompatible with other drug solutions.
Fluimucil ® with 500 mg / kg / day. does not cause signs and symptoms of overdose.
In a dark place at a temperature not exceeding 25 ° C.
Terms leave through pharmacies
Zambon S. P.A., Italy